Cayuga Biotech is a company headquartered in the United States.
Cayuga Biotech develops therapeutics that harness the body’s innate hemostatic mechanisms to treat life‑threatening hemorrhage and bleeding disorders. Its programs target noncompressible hemorrhage and coagulation dysfunctions such as those caused by platelet inhibitors.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.